Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 16/20 | 0.51 |
| ▸ | MTOR | P42345 | 6/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.47 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.46 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.46 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31711478 | 1.00 | PIK3CA (0.51) | PIK3CAMTORPIK3CDHDAC1PIK3R1 | |
| SCHEMBL13382857 | 1.00 | PIK3CA (0.51) | PIK3CAMTORPIK3CDHDAC1PIK3R1 | |
| SCHEMBL336392 | 1.00 | PIK3CA (0.51) | PIK3CAMTORPIK3CDHDAC1PIK3R1 | |
| Sulfuric Acid SCHEMBL337495 | 0.97 | PIK3CA (0.48) | PIK3CAMTORPIK3CDHDAC1PIK3R1 | |
| Sulfuric Acid SCHEMBL336041 | 0.97 | PIK3CA (0.48) | PIK3CAMTORPIK3CDHDAC1PIK3R1 | |
| SCHEMBL336465 | 0.96 | PIK3CA (0.48) | PIK3CAMTORPIK3CDHDAC1PIK3R1 | |
| SCHEMBL336218 | 0.96 | PIK3CA (0.48) | PIK3CAMTORPIK3CDHDAC1PIK3R1 | |
| SCHEMBL337173 | 0.93 | PIK3CA (0.44) | PIK3CAMTORPIK3CDHDAC1PIK3R1 | |
| SCHEMBL336675 | 0.93 | PIK3CA (0.44) | PIK3CAMTORPIK3CDHDAC1PIK3R1 | |
| SCHEMBL337158 | 0.93 | PIK3CA (0.51) | PIK3CAMTORPIK3CDHDAC1PIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339416-A1 | EZH1/2 DUAL INHIBITOR-CONTAINING PHARMACEUTICAL COMPOSITION TO BE USED AS A COMBINATION DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-11-06 | — | — | US | claimed |
| US-20210393601-A1 | EZH1/2 DUAL INHIBITOR-CONTAINING PHARMACEUTICAL COMPOSITION TO BE USED AS A COMBINATION DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-12-23 | — | — | US | claimed |
| EP-3888647-A1 | EZH1/2 DUAL INHIBITOR-CONTAINING PHARMACEUTICAL COMPOSITION TO BE USED AS COMBINATION DRUG | Daiichi Sankyo Company, Limited (JP) | 2021-10-06 | — | — | EP | claimed |
| CN-113164437-A | Pharmaceutical composition containing EZH1/2 dual inhibitor to be used as a combination drug | 第一三共株式会社 | 2021-07-23 | — | — | CN | claimed |
| EP-3266455-B1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING MTOR INHIBITOR | KOREA ADVANCED INST SCI & TECH (KR) | 2020-12-30 | — | — | EP | claimed |
| US-20250339416-A1 | EZH1/2 DUAL INHIBITOR-CONTAINING PHARMACEUTICAL COMPOSITION TO BE USED AS A COMBINATION DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-11-06 | — | — | US | disclosed |
| US-12390455-B2 | EZH1/2 dual inhibitor-containing pharmaceutical composition to be used as a combination drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-08-19 | — | — | US | disclosed |
| WO-2023285681-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | SPEXIS AG (CH) | 2023-01-19 | — | — | WO | disclosed |
| US-20210393601-A1 | EZH1/2 DUAL INHIBITOR-CONTAINING PHARMACEUTICAL COMPOSITION TO BE USED AS A COMBINATION DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-12-23 | — | — | US | disclosed |
| EP-3888647-A1 | EZH1/2 DUAL INHIBITOR-CONTAINING PHARMACEUTICAL COMPOSITION TO BE USED AS COMBINATION DRUG | Daiichi Sankyo Company, Limited (JP) | 2021-10-06 | — | — | EP | disclosed |
| CN-113164437-A | Pharmaceutical composition containing EZH1/2 dual inhibitor to be used as a combination drug | 第一三共株式会社 | 2021-07-23 | — | — | CN | disclosed |
| WO-2014185368-A1 | 5-{8-[(3R)-4-ACETYL-3-METHYLPIPERAZIN-1-YL]-6-MORPHOLIN-4-YL-9-(2,2,2-TRIFLUOROETHYL)-9H-PURIN-2-YL}PYRIMIDINE-2- AMINE AND NOVEL CRYSTAL OF PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF, AND METHOD FOR PRODUCING SAID CRYSTAL | 第一三共株式会社 (JP) | 2014-11-20 | — | — | WO | disclosed |
| US-8097622-B2 | Morpholinopurine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097622-B2 | Morpholinopurine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-17 | — | — | US | disclosed |
| EP-2336132-A1 | MORPHOLINOPURINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| EP-2336132-A1 | MORPHOLINOPURINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| WO-2010044401-A1 | MORPHOLINOPURINE DERIVATIVE | 第一三共株式会社 (JP) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339416-A1 | EZH1/2 DUAL INHIBITOR-CONTAINING PHARMACEUTICAL COMPOSITION TO BE USED AS A COMBINATION DRUG | EZH1, ZDHHC2, EZR | PIK3CA 1475/4885MTOR 1961/4885PIK3CD 1714/4885 |
| US-20210393601-A1 | EZH1/2 DUAL INHIBITOR-CONTAINING PHARMACEUTICAL COMPOSITION TO BE USED AS A COMBINATION DRUG | EZH1, ZDHHC2, EZR | PIK3CA 1475/4885MTOR 1961/4885PIK3CD 1714/4885 |
| US-12390455-B2 | EZH1/2 dual inhibitor-containing pharmaceutical composition to be used as a combination drug | EZH1, ZDHHC2, EZR | PIK3CA 1475/4885MTOR 1961/4885PIK3CD 1714/4885 |
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | MTOR, RICTOR, PIK3R1 | PIK3CA 22/4885MTOR 1/4885PIK3CD 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.